UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 5, 2012
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 001-33500 | 05-0563787 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
3180 Porter Drive, Palo Alto, California 94304
(Address of principal executive offices, including zip code)
(650) 496-3777
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On January 5, 2012, Jazz Pharmaceuticals, Inc. held an investor conference call, which included certain financial information relating to the year ended December 31, 2011. The conference call was announced by a widely disseminated press release and was made available to the public via audio webcast through Jazz Pharmaceuticals, Inc.’s website. A transcript of the relevant portion of the conference call relating to the aforementioned financial information is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and in the accompanying Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Jazz Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number |
Description | |
| 99.1 | Transcript of a portion of the conference call held by Jazz Pharmaceuticals, Inc. on January 5, 2012 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JAZZ PHARMACEUTICALS, INC. | ||
| By: |
/s/ Carol A. Gamble | |
| Carol A. Gamble | ||
| Senior Vice President and General Counsel | ||
Date: January 11, 2012
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Transcript of a portion of the conference call held by Jazz Pharmaceuticals, Inc. on January 5, 2012 | |
Exhibit 99.1
Transcript of the relevant portion of the conference call held by Jazz Pharmaceuticals, Inc.
4:30pm EST, January 5, 2012
[Kate Falberg, Senior Vice President and Chief Financial Officer, Jazz Pharmaceuticals, Inc.]
Turning to the balance sheet, we and Azur Pharma estimate that we ended 2011 with a combined cash balance of close to $240 million and no debt.